Strides Pharma Science (BOM:532531) Long-Term Capital Lease Obligation : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science Long-Term Capital Lease Obligation?

Strides Pharma Science's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil.

Strides Pharma Science's quarterly Long-Term Capital Lease Obligation increased from Jun. 2024 (₹0 Mil) to Sep. 2024 (₹620 Mil) but then declined from Sep. 2024 (₹620 Mil) to Dec. 2024 (₹0 Mil).

Strides Pharma Science's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (₹1,865 Mil) to Mar. 2023 (₹2,037 Mil) but then declined from Mar. 2023 (₹2,037 Mil) to Mar. 2024 (₹716 Mil).

Strides Pharma Science Long-Term Capital Lease Obligation Historical Data

The historical data trend for Strides Pharma Science's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Long-Term Capital Lease Obligation Chart

Strides Pharma Science Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2,538.33

2,102.67

1,864.67

2,036.74

716.35

Strides Pharma Science Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	716.35	-	619.51	-

Strides Pharma Science (BOM:532531) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Strides Pharma Science Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Strides Pharma Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

STAR:India

Address

Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076

Website

https://www.strides.com

Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines